评价RZL-012在颏下脂肪（SMF）堆积造成的中度至重度轮廓隆起或过度丰满人群中的疗效和安全性。疗效主要通过临床医师颏下脂肪评估工具（C-CAT）和受试者自我颏下脂肪评估工具（S-CAT）进行评价。使用临床医师颏下脂肪评估工具（C-CAT）和受试者自我颏下脂肪评估工具（S-CAT）（第12周与基线相比）评估RZL-012组和安慰剂组相比，临床医师和受试者评定的SMF丰满程度的变化。

开始日期2025-06-05

申办/合作机构

Raziel Therapeutics RT Ltd.

[+2]

NCT05763160

/ Completed临床2期

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of a Second Treatment Session of RZL-012 Into Submental Fat in Subjects Seeking Further Improvement

This is a Phase 2, open-label study in which subjects seeking further improvement of their SMF will be treated with a second treatment session of RZL-012.
The second treatment session will be offered to subjects previously treated with RZL-012 under protocols RZL-012-SMF-SWMTG-P2US-001 or RZL-012-SMFC-P2US-001. Subjects who fully completed either of the trials and whose C-CAT score is 2, 3 or 4 will be eligible to participate in the new trial.
For each subject, the study will consist of a screening period, baseline period in which subjects will receive a second treatment session of RZL-012 and a follow-up period. RZL-012 will be administered during a single treatment session via multiple injections into the submental area under the chin. Subjects will thereafter be monitored for safety and efficacy for at least 84 days.

开始日期2023-05-29

申办/合作机构

Raziel Therapeutics RT Ltd.

NCT05476679

/ Completed临床1/2期

An Open Label Phase 2 Study to Evaluate the Effects of a Local Anesthetic, Anti-inflammatory Medications and Compression Garments on RZL-012-Induced Adverse Events

This is a Phase 2, open-label, 2-stage, adaptive-design study in which subjects will be randomized into one of 5 treatment groups comprised of RZL-012 with or without additional study treatments:

开始日期2022-09-25

申办/合作机构

Raziel Health LLC

100 项与 RZL-012 相关的临床结果

登录后查看更多信息

100 项与 RZL-012 相关的转化医学

登录后查看更多信息

100 项与 RZL-012 相关的专利（医药）

登录后查看更多信息

项与 RZL-012 相关的文献（医药）

2023-09-14·Aesthetic surgery journal

Efficacy and Safety of Tapencarium (RZL-012) in Submental Fat Reduction

Article

作者: Steve Yoelin ; Michael Gold ; Racheli Gueta ; Sabrina Fabi ; Brian Biesman ; Glynis Ablon ; Derek Jones ; Patricia Walker ; Jeanine Downie ; Joel Cohen ; Ava Shamban ; Steven Fagien ; Sachin M Shridharani ; Steven Dayan

Abstract:

Background:

Tapencarium (RZL-012) (5-(3.6-dibromo-9H-carbazol-9-yl)-N, N, N-trimethylpentan-1-aminium chloride) is a novel injectable synthetic molecule with cytolytic properties, capable of reducing subcutaneous fat volume.

Objectives:

The goal of this 3-armed, randomized, double-blind, placebo-controlled phase 2b study was to determine the safety and efficacy of low- and high-dose RZL-012 vs placebo on submental fat (SMF) reduction.

Methods:

Patients (n = 151, age 18-65 years) with excess SMF received a single treatment session of RZL-012 or placebo in the submental area, after which they were monitored for 84 days. SMF was assessed at baseline and after dosing with newly developed scales, namely the Clinician Chin Assessment Tool (C-CAT) and Subject Chin Assessment Tool (S-CAT). SMF was also assessed by magnetic resonance imaging (MRI) at screening and on Day 84 after treatment.

Results:

The proportion of patients who had a 1-grade or 2-grade improvement in C-CAT and/or S-CAT on Day 84 vs baseline was significantly higher in the high-dose RZL-012 group vs the placebo group (P < .002). The relative percentage reduction in MRI-measured SMF volume (Day 84 vs screening) was significantly greater in the high-dose RZL-012 group vs the low-dose RZL-012 or the placebo group (P < .0001). Local injection site reactions were the most common adverse events (AEs).

Conclusions:

A single administration of RZL-012 into SMF resulted in significant improvement in submental appearance as assessed by clinicians, patients, and MRI. From a safety perspective, there were no serious AEs and no clinically significant changes in vital signs or laboratory tests over the course of the study.

Level of Evidence: 1:

2021-12-01·Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]3区 · 医学

Mode of Action of RZL-012, a New Fat-Reducing Molecule

3区 · 医学

Article

作者: Blaugrund, Eran ; Zernov, Anton ; Bloomenfeld, Alon ; Gueta, Racheli

BACKGROUND:

RZL-012 (5-[3,6-dibromo-9H-carbazol-9-yl]-N,N,N-trimethylpentan-1-aminium chloride) is a novel investigational drug injected subcutaneously into fat tissues in patients with fat-related disorders (Dercum disease) or subjects seeking aesthetic changes.

OBJECTIVE:

Preclinical studies were undertaken to understand RZL-012's mechanism of action.

MATERIALS AND METHODS:

The effects of RZL-012 were tested in vitro by measuring adipocyte cell killing, membrane integrity, cytosolic calcium, and mitochondrial membrane potential (MMP). In vivo studies in pigs evaluated RZL-012's adipocyte killing effect and measured pig fat thickness in the injected areas.

RESULTS:

RZL-012 triggered adipocyte cell killing with IC50 values ranging from 25 to 106 μM. RZL-012 demonstrated initial effects on membrane integrity and calcium levels with delayed alterations in MMP. Incubation of RZL-012 with nanoghosts increased membrane permeability, culminating in full membrane destruction. Analysis of injected areas in pigs revealed liponecrosis 24 hours after dosing followed by an inflammatory response and formation of fibrotic tissue. Three months after dosing, an 18% reduction in mean fat thickness was observed in RZL-012 treated pigs.

CONCLUSION:

RZL-012 destroys adipocytes by directly disrupting cell membrane integrity. Replacement of dead fat tissue by fibrotic tissue enables healing and causes contraction of the injected area. These effects are translated into significant reduction in fat tissue volume.

2021-08-01·Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]3区 · 医学

RZL-012, a New Fat Dissolving Molecule, Tested in Dercum's Disease Patients

3区 · 医学

Article

作者: Herbst, Karen L. ; Blaugrund, Eran ; Gueta, Racheli ; Bloomenfeld, Alon

RZL-012 [5-(3,6-dibromo-9H-carbazol-9-yl)-N,N,Ntrimethylpentan-l-aminium chloride] is a novel investigational drug intended for adipose tissue reduction on injection into s.c. fat.Based on in vitro and in vivo preclin. studies, the putative mechanism of action of RZL-012 seems to operate through induction of significant fat cell necrosis after a single injection with transient side effects, mostly at the injected area.An open label Phase 2a rial in 6 Dercum′s disease patients1,2 was undertaken to confirm initial safety and efficacy.Patients were dosed once by injecting the compound into painful lipomas.Lipoma height and pain were assessed at baseline, 28, and 56 days after injection.Lipomas demonstrated an average reduction of 48in height and 71in pain on Day 56 vs. baseine.The adverse event (AE) profile was benign without any serious AEs.

项与 RZL-012 相关的新闻（医药）

2026-03-09

·药创新

复健资本崔志平：中国创新药才走了20%，进阶机遇在何方？

一位CVC掌门人眼中的中国创新药进化论。撰文丨柴妍、黄思宇 “中国创新药追赶全球第一的路，我认为最多只走了20%。” 这是复星全球合伙人、复星总裁高级助理、复健资本联席CEO、新药基金总经理、创新药“华山奖”评审专家崔志平的研判。“抗体偶联药物（ADC）、T细胞衔接器（TCE）、小干扰RNA（siRNA）等既有技术赛道仍有内在的迭代潜力。ADC新型毒素的开发、双抗ADC的迭代都会产生新一轮机会。TCE正在向实体瘤和自免疾病不断开拓。siRNA领域亦然，从罕见病迈入慢病领域，将打开难以估量的新空间。这些都是留给中国创新药的机会。”他在接受“药创新”专访时说。 2025年，中国创新药BD出海授权呈现爆发式增长。全年交易总金额达到1357亿美元，同比增长161%；中国总交易金额全球占比已经达到49%，首次超越美国（27%）。这些数字意味着中国创新药从“跟随者”向“引领者”角色转变的历史性跨越——不再只是海外技术的接收方，而是以自主研发的创新资产，赢得全球顶级药企真金白银的认可。 2026年，创新药一级市场何时迎来“爆发式”复苏？如何更好地把握BD时机？中国创新药追赶“全球第一”的进阶过程中，有哪些新的投资机会？作为CVC（企业风险投资）标杆机构的掌舵人，崔志平向“药创新”阐述了他的判断与思考。复星全球合伙人、复星总裁高级助理、复健资本联席CEO、新药基金总经理、创新药“华山奖”评审专家崔志平做投资，“旋律”和“舞步”缺一不可 “做投资，不但对Alpha要有深刻认识，对Beta也要有敏锐感知。”崔志平开门见山。在他的框架里，Alpha代表的是价值发现——选择有价值的公司和赛道，这是投资的“旋律”；而Beta则是周期把握——什么时候进，什么时候退，这是投资的“舞步”。“我们团队经历过多轮资本周期，对这些理解非常深刻。”对于2026年的创新药行业趋势，崔志平的判断是：基本面依然强劲，快速发展势头仍将保持。去年中国创新药资本市场的驱动力主要是BD交易，体现了中国的创新竞争力。但也有说法认为中国创新药行业“工程师红利已过”“没有提升空间”，而他并不认同：“即使是目前竞争激烈的ADC领域，未来也可以做双抗ADC，双payload ADC，还可以开发新毒素……中国的工程师红利还可以持续发挥作用。” TCE也是如此。“T细胞上的CD3就像一匹骏马，指挥得好可以大杀四方，但如果没把住这个‘马头’，就可能发生细胞因子风暴（CRS）等免疫反应，此前开发失败的部分TCE也是这个原因，因此TCE也有很大的优化空间。”崔志平分析道。 “基因治疗和细胞治疗更是‘蓝海刚刚打开’。小核酸如果能做到‘指哪打哪’，尤其是肝外靶向，那会是不得了的突破。不久的将来，我们很有可能在中国资本市场看到基因治疗和细胞治疗公司的上市潮，这一波一波的技术红利会持续释放。”崔志平预测。从疾病领域看，慢病领域有庞大的未满足治疗需求，国内开发抗体药物的创新药企也在逐渐从肿瘤转向自免、内分泌代谢等慢性病，亦可视为未来国内创新药市场的增长动能。 2025年7月，中国生物制药宣布收购礼新，是中国创新药企收/并购史上的里程碑事件。崔志平认为，本土“大药企”成长到一定阶段需要补充管线，而本土Biotech的竞争力也在提升，将成为潜在的收/并购对象。与此同时，在政策、行业竞争等的影响下，大批中成药和仿制药企业正尝试转型做创新药，并设立创新药研发基金。崔志平分析，对其中一些规模较大的企业而言，由于初期缺乏研发经验，直接购买可以降低风险，由此满足对创新药管线的需求。基于此，他对2026年的创新药一级市场保持乐观，并给出了清晰的逻辑推演——去年港股创新药公司上市后，很多偏财务型的基石投资者在半年锁定期结束后会陆续退出，而这些钱又会返回来投基金。因此，创新药一级市场从今年下半年开始预计会迎来更为强劲的复苏。早期管线BD未必要接受“低价”命运在市场一片繁荣的背景下，也暗含BD“卖青苗”的隐忧，BD交易的时机与定价成为业界讨论的焦点。一边是“有BD就涨”的市场热情，另一边是“BD过早、金额偏低”的质疑声音。崔志平给出了他的框架性思考：BD的最优时机，需要结合企业发展阶段和管线供需关系来通盘考量。崔志平用一个直白的比喻阐述他的观点：“就像你养了很多孩子，如果家里缺钱就只能早点把孩子嫁出去；如果不缺钱完全可以让孩子读完哈佛再嫁，身价更高。BD的时机很多时候要看公司的资金状况。” 其次还要看买方的需求。买家有不同类型，有的追求First-in-Class早期管线，有的买家更保守，要看到POC数据才敢下手——因此，他们购买的管线阶段是完全不同的。对于首付款比例，崔志平援引了一个令人警醒的数据：国际上早期管线BD首付款占总金额的比例一般是15%至20%，但2024年至2025年，中国BD交易的平均首付款比例普遍偏低，甚至有些已处于II期临床阶段的产品首付款仅占BD总金额的5%至6%。“这反映出市场竞争加剧，”他直言，“供方多了，价格自然下来。” 但这并不意味着早期管线就必须接受“低价”的命运，临床数据仍是撬动BD金额的关键杠杆。“能把疗效门槛抬得很高，后继者很难超越，这才是好品种，卖出的都是好价钱。”崔志平直截了当地指出。复星医药开发的口服小分子GLP-1R激动剂（YP05002）就是典型例子，这款仅处于海外I期临床的管线，以20.85亿美元的最高交易总金额授权给辉瑞，创下中国创新药出海早期阶段交易总金额纪录，正是因为其分子设计优势，以及在临床前研究中显示出优异的药代动力学特性和减重效果。在BD策略上，崔志平提出了一个颇具复健资本特色的框架：海外做BD，国内做IPO或被收/并购。“海外买家倾向于完整买断产品权益，国内则适合通过IPO或被收/并购来退出，”他解释说，“两者组合起来，就是我们基金的退出策略。” 这套策略背后，是以复健资本独特的CVC（企业风险投资）模式做支撑。复健资本新药创新基金由复星医药于2020年8月设立，首期规模15亿元。与纯财务型基金截然不同，复健资本采用控股孵化模式——从0到1主导企业建立，先确定技术赛道战略，再寻找科学家、组建团队。 “我们不是参股型基金，是控股孵化，”崔志平强调，“苦活、累活、难搞的活，都是我们自己干。从研发到管理，从融资到BD，我们是全流程参与的。”他用“全能选手”来描述这套模式的核心竞争力：“我们的团队既懂技术，又懂管理和资本市场。单靠某一技术赛道的一时领先，只是偶然的成功。只有全面的综合能力，才是可持续的成功，也是我们的‘护城河’所在。” 目前，复健资本已孵化包括星曜坤泽、星奥拓维、星明优健、星赛瑞真、星魅生物在内的10个前沿技术企业，涵盖基因疗法、核酸类药物、干细胞、小型化偶联药物等领域。在管线进展上，已有多个项目取得标志性突破：星曜坤泽聚焦肝病治疗，其自主研发的HT-101是一款靶向乙肝表面抗原（HBsAg）的siRNA创新药，旨在实现乙肝患者“功能性治愈”，填补现有疗法需终身服药且无法治愈的巨大临床空白。管线Ib期临床数据已足够亮眼——单药仅两针，高剂量组患者HBsAg即持续下降超3个数量级，部分患者实现清除；而与中和抗体HT-102联合治疗的数据更令人振奋：第24周联合治疗组HBsAg总转阴率达79%，其中高剂量组在第20周即有90%患者实现HBsAg清除，刷新乙肝“功能性治愈”疗效纪录。复健资本孵化的另一家基因治疗公司星奥拓维，主攻OTOF、GJB2等基因缺陷导致的先天性听力损失，其代表性管线OTOV-101（双载体AAV递送基因疗法）已在临床试验中恢复多例患者听力，并已获得美国FDA孤儿药认定。礼来至今已三次引进听力损失基因疗法，预示该领域蕴含较大BD机会。复健资本旗下的星明优健在2025年10月宣布，将基于光遗传学技术开发的创新眼科基因疗法UGX202授权给英国公司AviadoBio，潜在适应症包括视网膜色素变性、晚期干性年龄相关黄斑病变等，交易最高总金额超4亿美元，标志着中国眼科基因疗法首次以License-out形式出海。星赛瑞真是复健资本旗下再生医学的先锋，手握细胞治疗的“万能钥匙”，正在向糖尿病“功能性治愈”发起终极冲锋。公司深耕诱导多能干细胞（iPSC）疗法，重新定义了糖尿病治疗标准——不再只是控制血糖，而是重建患者的血糖自主调控能力，有望让患者告别胰岛素针头。崔志平对这条管线充满信心，并将其描述为“刚刚打开细胞再生领域的蓝海。” 此外，复健资本还孵化了星魅生物，它是医美赛道的“隐形冠军”。核心产品RZL-012瞄准的是医美市场最大的空白、影响超千万人群的“颜值杀手”——双下巴（颏下脂肪堆积）。2024年8月，星魅生物与轻医美龙头中科康美达成战略投资合作，成为复健资本新药基金首个实现部分退出的孵化项目。复健资本所孵化的项目群，正遵循前沿生命科学技术领域的系统性布局思路，秉持深度赋能的孵化理念，不断将这一模式转化为实际成果。它已超越了单纯投资基金的范畴，正成为中国下一代生物技术创新的关键策源地。 “全球第一”之路如何进阶？崔志平认为，中国创新药要追赶全球第一，这条路目前只走了20%。在这道阻且长的征途中，如果始终依赖工程师红利的单一优势，迟早要面临发展瓶颈。未来靠什么进阶？崔志平给出了三个方向：前沿技术的突破、尚待开拓的蓝海疾病市场、在AI制药竞赛中抢占先机。首先是前沿技术突破，细胞与基因治疗（CGT）是崔志平较为看好的技术赛道。早在2014年，崔志平就意识到衣壳（基因治疗载体的蛋白质外壳）工程化是这一领域的核心壁垒，改造成功的衣壳在保护基因治疗药物、降低免疫原性、递送靶向性等方面均具有优势。正是基于这一战略判断，星明优健和星奥拓维两家基因治疗公司自成立之初就将自研衣壳能力作为建设方向。 “CGT领域的技术红利还未充分释放。”崔志平指出，CGT的终极价值是实现一次给药、终身获益——神经系统疾病、内分泌代谢疾病、衰老等相关疾病，都有望通过基因层面的干预实现根本性治疗。其次，疾病谱的演变正催生出新的蓝海市场。崔志平注意到，过去十年，国内大量创新药公司聚焦肿瘤和自身免疫两大赛道，但随着多种肿瘤的5年生存期延长，癌症逐步向慢病属性转化。“创新药的下一个爆发窗口将向代谢疾病、心血管疾病、CNS（中枢神经系统）等大慢病领域迁移。”他预判道。而当前抗体类药物的用途已经从肿瘤延伸到减肥等代谢领域，也正印证着这一趋势。第三个重大变量是AI与制药的融合。“真正最具有颠覆性的还是AI制药，这是未来中美创新药之争的关键变量，谁抢得先机，谁就可能拥有后续多年的领先优势。如果我们在AI制药的竞争中落后，前进的步伐就会慢很多。”崔志平特别强调道。他指出，AI在制药领域的价值演变会有两个维度：第一个是提升效率。把几个月的实验室任务压缩到几周内，把几年的临床试验周期持续压缩；第二个是药物发现。不是对药物简单改进，而是利用AI生成人类难以发现的、全新骨架的分子。“做人类做不了的事，颠覆医药研发的范式。”他充满期待地说道。中国创新药的时代序章已经翻开，驱动这场变革的正是像复健资本这样的参与者——既有对前沿科学的敏锐判断，又有陪伴企业穿越周期的耐心与能力。从HT-101的乙肝“功能性治愈”突破，到开创眼科基因疗法出海的先河，复健资本的每一个孵化成果，都在推动着中国创新药行业的整体跃升。未来，随着基因治疗、细胞治疗等技术突破次第涌来，复健资本所深耕领域的爆发，将不是巧合，而是前瞻布局的必然回报。 END 作者简介往期精彩内容诺和诺德全球首创新药在华获批；罗氏公布amylin减重临床数据当“重磅炸弹”哑火：Rocatinlimab叫停背后，特应性皮炎赛道的危与机新一代偏向型GLP-1药物减重获批！埃诺格鲁肽带来肥胖治疗新方案

2025-11-08

·皖医二附院皮肤科

中重度斑块状银屑病患者招募

患者 11月7日 11月7日中午，我院皮肤科召开“一项前瞻性、单臂、多中心、IV期研究以评估其他生物制剂转换为夫那奇珠单抗治疗成人中重度斑块状银屑病的有效性及安全性(V-TRANSITION)项目”启动会。会议内容银屑病相关知识银屑病（psoriasis，PsO）是遗传与环境共同作用诱发的免疫介导的慢性、复发性、炎症性、系统性皮肤病。数据显示，各国银屑病患病率在0.09%至11.43%之间，2008年中国6省市银屑病流行病学调查结果为0.47%；银屑病约影响全球1.25亿人，我国患者超过764万例，近60%患者的病程年限超过10年，超过50%的患者为中重度银屑病患者。对于中重度斑块状银屑病，主要采用系统药物治疗：包括传统口服药物（维A酸类药物、甲氨蝶呤、环孢素等）和生物制剂。目前我国已获批上市的生物制剂种类有TNF-αi、IL-17Ai、IL-12/23i、IL-23i 等。生物制剂的应用为患者带来很大获益。 01 入组标准 1. 年龄≥18岁，性别不限； 2. 诊断为中重度斑块状银屑病； 3. 受试者在研究相关的任何程序开始前自愿签署知情同意，能够与研究者顺利交流，理解并愿意严格遵守本临床研究方案的要求完成研究； 4. 筛选前使用过生物制剂治疗≥12周，符合《中国银屑病生物制剂及小分子药物治疗指南（2024版）》生物制剂转换建议，且经研究者筛选评估可接受生物制剂治疗的患者。 02 联系方式如果您满足以上条件，且有意参加或有兴趣进一步了解该项研究更多信息，请与下面医生联系：联系人及电话：凌晓雅医师 19883418993（微信同号）医院地址：安徽省芜湖市镜湖区康复路10号皖南医学院第二附属医院其他项目 1.激光、光子术后患者招募 https://mp.weixin.qq.com/s/lKcjiN3S9PRb2G0rC9posA 2.寻常痤疮受试者招募 https://mp.weixin.qq.com/s/0gXxYuBdUt2IxJe3chZ1_Q 3.敏感性肌肤招募 https://mp.weixin.qq.com/s/1pE4GfvAfyYh_iiDFKDIww 4.斑秃患者招募 https://mp.weixin.qq.com/s/1hvxH-NNa9umAKfmmHRDow 5.3-24月龄特应性皮炎患者招募 https://mp.weixin.qq.com/s/-lUE_xq36l4-_mC8UL5W4g 6.带状疱疹后神经痛患者招募 https://mp.weixin.qq.com/s/V1K-MnRHPmBILoQI4qZeLA 7.鼻唇沟填充受试者招募 https://mp.weixin.qq.com/s/gbYd3y3iLoHQMlRUQCC_8g 8.RZL-012治疗颏下脂肪堆积患者招募 https://mp.weixin.qq.com/s/ri5gbpqvVWYMmwGP5IwptA 9.斑块状银屑病患者招募 https://mp.weixin.qq.com/s/MoAdpXEeZ_8RuOhPytdHJg 10.青少年中重度特应性皮炎患者招募 https://mp.weixin.qq.com/s/g2Wjt7TnAmlpMol11EeteA 11.复发性口唇疱疹患者招募 https://mp.weixin.qq.com/s/yZet3mN9VCG5tzEchkdr8Q 12.特应性皮炎患者招募 https://mp.weixin.qq.com/s/Fv3Q6YdVxXuv6rqBRj8leg 文案 | 秦蕾一审 | 秦蕾二审 | 方玉霞终审| 吴丽 END 扫码关注皖南医学院第二附属医院皮肤科获取更多精彩资讯

上市批准临床研究临床结果

2025-03-03

·PRNewswire

Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction ("double chin")

REROVOT, Israel, March 3, 2025 /PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 study initiation in China for the treatment of fat reduction in the submental area. Submental fat (SMF) reduction is the first indication for RZL-012 among many potential aesthetic focal fat reduction treatments for body shaping. RZL-012 is an injectable lipolytic drug being developed for the reduction of unwanted submental fat ("double-chin") or fat in other body areas, in adults. The compound is injected subcutaneously into submental fat tissue in 1-2 injection sessions by trained physicians and destroys fat cells, resulting in fat volume reduction and improved appearance of the injected area. Raziel Therapeutics and Tianjin JuveStar Biotech Co., Ltd., (JuveStar), a company invested and incubated by the venture capital arm of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196.SH, 02196.HK), partnered with Raziel Therapeutics to develop RZL-012 and JuveStar holds the commercial rights for RZL-012 in Greater China. A phase 3 study will be initiated in China during the upcoming few weeks. JuveStar will be responsible for conducting the phase 3 study, while Raziel will be responsible for manufacturing the drug substance and finished drug product for the clinical activities in China. The product is expected to be launched in China during 2027. "The initiation of phase 3 study in the China market is a significant progress, we believe that RZL 012 will be a lead drug for focal fat reduction in China" said Alon Bloomenfeld Founder and CEO of Raziel therapeutics. Fosun Pharma is one of the leading healthcare companies in China, with expertise and access to both the aesthetic and therapeutic markets. The collaboration will enrich Fosun Pharma's pipeline in the field of medical aesthetics and provide more options for the unmet clinical needs. The market for focal reduction of resistant fat based therapies, has high potential and is complementary to the widespread use of weight loss therapies. The benefit of using RZL-012 is its ability to target focal or localized unwanted fat with only 1-2 treatment cycles. About Submental Fullness Submental fullness is a common yet undertreated condition that can detract from an otherwise balanced and harmonious facial appearance – leading to an older and heavier look. Submental fullness can affect adults – both women and men – of all ages, weights and genders. Influenced by multiple factors including aging and genetics, submental fullness is often resistant to diet and exercise. About RZL - 012 RZL-012 is a novel small molecule entity formulated with no human and no animal related components. When injected into subcutaneous fat, RZL-012 destroys fat cells and reduces fat volume. Once destroyed, those cells can no longer store or accumulate fat. About Fosun Pharma: Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business. Fosun Pharma is patient-centered and unmet clinical needs-oriented. Through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and industrial investment, the company continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma's innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules. Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma adheres to the business philosophy of "Innovation for Good Health", continues to promote innovative transformation, actively deploys internationalization, strengthens business focus by product lines, promotes integrated operations and efficiency improvement, and is dedicated to being the global leading integrator of pharmaceutical and healthcare innovation. For more information, please visit: . About Raziel Therapeutics. Raziel Therapeutics is an emerging Israeli based pharmaceutical leader developing a disruptive technology for the treatment of aesthetic indications. Raziel has developed a unique proprietary compound by obtaining a License from the Hebrew university. The company's lead compound, RZL-012, is in phase 2 or 3 clinical development for a broad range of aesthetic indications. More information on Raziel Therapeutics may be found at Contact: Alon Bloomenfeld [email protected] +972542325070 SOURCE Raziel Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期

100 项与 RZL-012 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部肥胖	临床3期	中国	Raziel Therapeutics, Ltd.	2025-03-03
局部肥胖	临床3期	中国	上海复星医药（集团）股份有限公司	2025-03-03
痛性肥胖症	临床2期	美国	Raziel Therapeutics RT Ltd.	2018-06-28
脂肪水肿	临床2期	美国	Raziel Therapeutics RT Ltd.	2018-06-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03492840 (CTgov)	临床2期	痛性肥胖症 \| 脂肪水肿	12	RZL-012	衊淵壓積繭構淵淵築壓 = 廠糧積鑰齋衊醖餘窪築壓淵憲壓廠憲憲顧襯糧 (壓簾鏇網鑰襯網鏇範艱, 窪廠積憲構壓糧憲構襯 ~ 繭選壓鏇製醖艱積獵鹽) 更多	-	2024-02-08
NCT04229030 (CTgov)	临床2期	痛性肥胖症	38	RZL-012 (RZL-012)	製壓醖鹹齋膚願願膚築(壓壓鹹壓艱鬱顧餘鑰築) = 鏇糧繭窪窪窪襯遞構製簾構獵鑰廠鏇觸襯齋繭 (醖願鹹艱膚鏇艱願襯構, 25.56) 更多	-	2024-02-07
				Vehicle (Vehicle of RZL-012)	製壓醖鹹齋膚願願膚築(壓壓鹹壓艱鬱顧餘鑰築) = 獵構繭獵壓鏇壓憲糧繭簾構獵鑰廠鏇觸襯齋繭 (醖願鹹艱膚鏇艱願襯構, 23.96) 更多
NCT05466448 (CTgov)	临床1/2期	-	20	RZL-012 (Chinese)	顧廠鑰積簾獵製夢範齋(遞憲選遞鬱顧艱壓廠築) = 糧壓襯簾糧獵鹹膚衊構窪鬱艱膚鏇淵襯淵衊廠 (築觸鬱艱鏇廠餘餘獵鹹, 183.6) 更多	-	2023-12-19
				RZL-012 (Non-Chinese)	顧廠鑰積簾獵製夢範齋(遞憲選遞鬱顧艱壓廠築) = 艱膚範遞艱鏇範憲艱鹹窪鬱艱膚鏇淵襯淵衊廠 (築觸鬱艱鏇廠餘餘獵鹹, 186.8) 更多
NCT04086823 (CTgov)	临床2期	局部肥胖	28	Placebo (Vehicle)	鹽網繭憲鏇積簾網積範 = 醖範夢壓憲蓋鏇鹹蓋繭鏇鬱積衊選鬱構網簾憲 (壓鹹夢鹽醖觸蓋窪餘醖, 選繭簾選蓋鹽醖顧廠鹹 ~ 膚鏇願鬱艱簾繭鬱顧襯) 更多	-	2023-11-18
				RZL-012 (RZL-012)	顧觸願願選壓壓夢築糧(選艱獵範鬱壓鹽齋蓋鏇) = 製獵餘艱繭蓋窪鹹壓窪製鏇築獵艱鑰襯膚簾壓 (夢遞廠壓鹽顧衊襯範願, 8) 更多
NCT05445557 (CTgov)	临床2期	-	12	RZL-012 (RZL-012 50mg/ml)	鏇廠蓋觸壓廠鏇蓋鹹艱 = 壓願獵觸襯簾壓網衊鑰繭繭構鏇夢積願繭憲夢 (艱積繭製窪夢鑰鏇衊廠, 鬱築積築繭鏇鬱艱獵衊 ~ 憲膚鏇製憲夢願製憲鬱) 更多	-	2023-11-18
				Placebo (Placebo)	鏇廠蓋觸壓廠鏇蓋鹹艱 = 膚願憲觸廠餘構壓鏇顧繭繭構鏇夢積願繭憲夢 (艱積繭製窪夢鑰鏇衊廠, 窪餘鹹淵鹽鹽獵憲獵獵 ~ 願襯壓鑰壓遞艱鬱製築) 更多
NCT04867434 (CTgov)	临床2期	-	151	RZL-012 (RZL-012 50mg/ml)	選獵齋鑰製鬱蓋憲廠鏇 = 鑰廠膚積網齋選願齋襯選顧網鹹餘網鏇蓋獵窪 (網醖遞鏇顧膚選鹽鬱獵, 糧遞願蓋衊夢廠艱網築 ~ 鬱糧築鏇鏇網餘壓願醖) 更多	-	2023-09-28
				RZL-012 (RZL-012 34mg/ml)	選獵齋鑰製鬱蓋憲廠鏇 = 網鏇廠選製壓襯鹽築鏇選顧網鹹餘網鏇蓋獵窪 (網醖遞鏇顧膚選鹽鬱獵, 膚鹽齋繭夢網觸鏇構艱 ~ 艱獵繭衊鏇蓋憲衊餘廠) 更多
NCT03171415 (CTgov)	临床2期	肥胖	32	Placebo	齋範遞蓋簾鑰蓋遞餘獵 = 構構夢襯觸壓膚願鏇窪顧淵襯鹽遞鏇醖簾選願 (鬱積遞壓鬱遞顧構襯獵, 鏇淵餘鏇獵選願壓繭築 ~ 糧鏇積餘艱淵鏇壓蓋願) 更多	-	2019-08-21